FDAnews Drug Daily Bulletin

BRADLEY ENTERS INTO DOXYCYCLINE MONOHYDRATE AUTHORIZED GENERIC LICENSING AGREEMENT WITH PAR

Dec. 16, 2005
A A

Bradley Pharmaceuticals today announced that the Company has entered into a Licensing and Distribution Agreement with Par Pharmaceuticals Companies, Inc. (NYSE: PRX). Pursuant to this Agreement, Bradley has granted Par a license to be Bradley's exclusive distributor throughout the United States of Bradley's authorized generic version of the 50mg and 100mg strengths of ADOXA doxycycline monohydrate tablets, an antibiotic therapy primarily used for the adjunctive treatment of severe acne.

PR Newswire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/12-14-2005/0004234366&EDATE=)